Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy

References

• 1. Steller H. Mechanisms and genes of cellular suicide. Science 267(5203), 1445–1449 (1995).
  Medline CASGoogle Scholar
• 2. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 88(3), 347–354 (1997).
  Medline CASGoogle Scholar
• 3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57–70 (2000).
  Medline CASGoogle Scholar
• 4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 5. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2), 153–164 (2002).
  Medline CASGoogle Scholar
• 6. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer. biol. Ther. 4(2), 139–163 (2005).
  Medline CASGoogle Scholar
• 7. Roy S, Nicholson DW. Cross-talk in cell death signaling. J. Exp. Med. 192(8), F21–25 (2000).
  Medline CASGoogle Scholar
• 8. Wilson NS, Yang A, Yang B et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer cell 22(1), 80–90 (2012).
  Medline CASGoogle Scholar
• 9. Pitti RM, Marsters SA, Ruppert S et al. Induction of apoptosis by apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271(22), 12687–12690 (1996).
  Medline CASGoogle Scholar
• 10. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug. Discov. 7(12), 1001–1012 (2008).
  Medline CASGoogle Scholar
• 11. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble apo2 ligand. J. Clin. Invest. 104(2), 155–162 (1999).
  Medline CASGoogle Scholar
• 12. Chuntharapai A, Dodge K, Grimmer K et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166(8), 4891–4898 (2001).
  Medline CASGoogle Scholar
• 13. Jin H, Yang R, Ross J et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin. Cancer Res. 14(23), 7733–7740 (2008).
  Medline CASGoogle Scholar
• 14. Marini P, Junginger D, Stickl S et al. Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Radiat. Oncol. 4, 49 (2009).
  MedlineGoogle Scholar
• 15. Luster TA, Carrell JA, McCormick K et al. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther. 8(2), 292–302 (2009).
  Medline CASGoogle Scholar
• 16. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell. Death. Differ. 21(9), 1350–1364 (2014).
  Medline CASGoogle Scholar
• 17. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14(3–4), 337–348 (2003).
  Medline CASGoogle Scholar
• 18. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53), 8628–8633 (2003).
  Medline CASGoogle Scholar
• 19. Hymowitz SG, Christinger HW, Fuh G et al. Triggering cell death: the crystal structure of apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4(4), 563–571 (1999).
  Medline CASGoogle Scholar
• 20. Yuan X, Gajan A, Chu Q et al. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 37(4), 733–748 (2018).
  Medline CASGoogle Scholar
• 21. Pan G, O'Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 276(5309), 111–113 (1997).
  Medline CASGoogle Scholar
• 22. Schneider P, Bodmer JL, Thome M et al. Characterization of two receptors for TRAIL. FEBS Lett. 416(3), 329–334 (1997).
  Medline CASGoogle Scholar
• 23. Walczak H, Degli-Esposti MA, Johnson RS et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. The EMBO J. 16(17), 5386–5397 (1997).
  Medline CASGoogle Scholar
• 24. Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327), 818–821 (1997).
  Medline CASGoogle Scholar
• 25. Degli-Esposti MA, Smolak PJ, Walczak H et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186(7), 1165–1170 (1997).
  Medline CASGoogle Scholar
• 26. Marsters SA, Sheridan JP, Pitti RM et al. A novel receptor for apo2L/TRAIL contains a truncated death domain. Curr. Biol. CB 7(12), 1003–1006 (1997).
  Medline CASGoogle Scholar
• 27. Degli-Esposti MA, Dougall WC, Smolak PJ et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7(6), 813–820 (1997).
  Medline CASGoogle Scholar
• 28. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273(23), 14363–14367 (1998).
  Medline CASGoogle Scholar
• 29. Dufour F, Rattier T, Constantinescu AA et al. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. Oncotarget 8(6), 9974–9985 (2017).
  MedlineGoogle Scholar
• 30. Peter ME. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Differ. 7(9), 759–760 (2000).
  Medline CASGoogle Scholar
• 31. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275(33), 25065–25068 (2000).
  Medline CASGoogle Scholar
• 32. Jin Z, Li Y, Pitti R et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137(4), 721–735 (2009).
  Medline CASGoogle Scholar
• 33. Gonzalvez F, Lawrence D, Yang B et al. TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol. Cell 48(6), 888–899 (2012).
  Medline CASGoogle Scholar
• 34. Schug ZT, Gonzalvez F, Houtkooper RH et al. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 18(3), 538–548 (2011).
  Medline CASGoogle Scholar
• 35. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat. Rev. Mol. Cell. Biol. 2(7), 550–556 (2001).
  Medline CASGoogle Scholar
• 36. Jost PJ, Grabow S, Gray D et al. XIAP discriminates between Type I and Type II FAS-induced apoptosis. Nature 460(7258), 1035–1039 (2009).
  Medline CASGoogle Scholar
• 37. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol. 16(5), 264–272 (2006).
  Medline CASGoogle Scholar
• 38. Pardo J, Perez-Galan P, Gamen S et al. A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J. Immunol. 167(3), 1222–1229 (2001).
  Medline CASGoogle Scholar
• 39. Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J. Biol. Chem. 273(10), 5841–5845 (1998).
  Medline CASGoogle Scholar
• 40. Shisler JL. Viral and cellular FLICE-inhibitory proteins: a comparison of their roles in regulating intrinsic immune responses. J. Virol. 88(12), 6539–6541 (2014).
  MedlineGoogle Scholar
• 41. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 388(6638), 190–195 (1997).
  Medline CASGoogle Scholar
• 42. Golks A, Brenner D, Fritsch C et al. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 280(15), 14507–14513 (2005).
  Medline CASGoogle Scholar
• 43. Krueger A, Schmitz I, Baumann S et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276(23), 20633–20640 (2001).
  Medline CASGoogle Scholar
• 44. Schneider P, Thome M, Burns K et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7(6), 831–836 (1997).
  Medline CASGoogle Scholar
• 45. Lin Y, Devin A, Cook A et al. The death domain kinase RIP is essential for TRAIL (apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20(18), 6638–6645 (2000).
  Medline CASGoogle Scholar
• 46. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280(16), 15709–15718 (2005).
  Medline CASGoogle Scholar
• 47. Tran SE, Holmstrom TH, Ahonen M et al. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276(19), 16484–16490 (2001).
  Medline CASGoogle Scholar
• 48. Varfolomeev E, Maecker H, Sharp D et al. Molecular determinants of kinase pathway activation by apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280(49), 40599–40608 (2005).
  Medline CASGoogle Scholar
• 49. Ehrhardt H, Fulda S, Schmid I et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22(25), 3842–3852 (2003).
  Medline CASGoogle Scholar
• 50. Iurlaro R, Munoz-Pinedo C. Cell death induced by endoplasmic reticulum stress. FEBS J. 283(14), 2640–2652 (2016).
  Medline CASGoogle Scholar
• 51. Huang Y, Wang Y, Li X et al. Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages. FEBS J. 282(12), 2361–2378 (2015).
  Medline CASGoogle Scholar
• 52. Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, casper, and caspase-8. The J. Biol. Chem. 275(15), 10838–10844 (2000).
  Medline CASGoogle Scholar
• 53. Grunert M, Gottschalk K, Kapahnke J et al. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-kappaB by TRAIL. Cell Death Dis. 3, e414 (2012).
  Medline CASGoogle Scholar
• 54. O'Leary L, van der Sloot AM, Reis CR et al. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene 35(10), 1261–1270 (2016).
  MedlineGoogle Scholar
• 55. Mert U, Sanlioglu AD. Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. Cell. Mol. Life Sci. 74(2), 245–255 (2017).
  Medline CASGoogle Scholar
• 56. Austin CD, Lawrence DA, Peden AA et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl. Acad. of Sci. USA 103(27), 10283–10288 (2006).
  Medline CASGoogle Scholar
• 57. Kohlhaas SL, Craxton A, Sun XM et al. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282(17), 12831–12841 (2007).
  Medline CASGoogle Scholar
• 58. Akazawa Y, Mott JL, Bronk SF et al. Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 136(7), 2365–2376 e2361–2367 (2009).
  MedlineGoogle Scholar
• 59. Kojima Y, Nakayama M, Nishina T et al. Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. J. Biol. Chem. 286(50), 43383–43393 (2011).
  Medline CASGoogle Scholar
• 60. Yerbes R, Lopez-Rivas A, Reginato MJ, Palacios C. Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells. Cell Death Differ. 19(12), 1908–1916 (2012).
  Medline CASGoogle Scholar
• 61. Li C, Egloff AM, Sen M et al. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol. Oncol. 8(7), 1220–1230 (2014).
  Medline CASGoogle Scholar
• 62. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12(3), 228–237 (2005).
  Medline CASGoogle Scholar
• 63. Ion GND, Nitulescu GM, Popescu CI. Targeting TRAIL. Bioorg. Med. Chem. Lett. 29(18), 2527–2534 (2019).
  Medline CASGoogle Scholar
• 64. Coletta RD, Christensen KL, Micalizzi DS et al. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 68(7), 2204–2213 (2008).
  Medline CASGoogle Scholar
• 65. Wong SHM, Kong WY, Fang CM et al. The TRAIL to cancer therapy: Hindrances and potential solutions. Crit. Rev. Oncol. Hematol. 143, 81–94 (2019).
  MedlineGoogle Scholar
• 66. Yang J, Li G, Zhang K. Pro-survival effects by NF-kappaB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. Biomed. Pharmacother. 84, 1078–1087 (2016).
  Medline CASGoogle Scholar
• 67. Yang M, Liu L, Xie M et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy 11(2), 214–224 (2015).
  MedlineGoogle Scholar
• 68. Somasekharan SP, Koc M, Morizot A et al. TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. Apoptosis 18(3), 324–336 (2013).
  Medline CASGoogle Scholar
• 69. Romano G, Acunzo M, Garofalo M et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc. Natl. Acad. Sci. USA 109(41), 16570–16575 (2012).
  Medline CASGoogle Scholar
• 70. Krebs M, Behrmann C, Kalogirou C et al. miR-221 augments TRAIL-mediated apoptosis in prostate cancer cells by inducing endogenous TRAIL expression and targeting the functional repressors SOCS3 and PIK3R1. Biomed res. Int. 2019, 6392748 (2019).
  MedlineGoogle Scholar
• 71. Lv J, Guo T, Qu X et al. PD-L1 under regulation of miR-429 influences the sensitivity of gastric cancer cells to TRAIL by binding of EGFR. Front. Oncol. 10, 1067 (2020).
  MedlineGoogle Scholar
• 72. Ma W, Cui Y, Liu M et al. Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein. Aging 11(9), 2670–2680 (2019).
  MedlineGoogle Scholar
• 73. Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front. Oncol. 5, 69 (2015).
  MedlineGoogle Scholar
• 74. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26(21), 3621–3630 (2008).
  Medline CASGoogle Scholar
• 75. Von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat. Rev. Cancer 17(6), 352–366 (2017).
  Medline CASGoogle Scholar
• 76. Ganten TM, Koschny R, Sykora J et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. cancer Res. 12(8), 2640–2646 (2006).
  Medline CASGoogle Scholar
• 77. Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant apo2L/TRAIL versions. Nat. Med. 7(4), 383–385 (2001).
  Medline CASGoogle Scholar
• 78. Kelley SK, Harris LA, Xie D et al. Preclinical studies to predict the disposition of apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. and Exp. Ther. 299(1), 31–38 (2001).
  Medline CASGoogle Scholar
• 79. Herbst RS, Eckhardt SG, Kurzrock R et al. Phase I dose-escalation study of recombinant human apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 28(17), 2839–2846 (2010).
  Medline CASGoogle Scholar
• 80. Subbiah V, Brown RE, Buryanek J et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol. cancer Ther. 11(11), 2541–2546 (2012).
  Medline CASGoogle Scholar
• 81. Xiang H, Nguyen CB, Kelley SK et al. Tissue distribution, stability, and pharmacokinetics of apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispo. 32(11), 1230–1238 (2004).
  Medline CASGoogle Scholar
• 82. Merino D, Lalaoui N, Morizot A et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 26(19), 7046–7055 (2006).
  Medline CASGoogle Scholar
• 83. Thapa B, Kc R, Uludag H. TRAIL therapy and prospective developments for cancer treatment. J. Control. Release 326, 335–349 (2020).
  Medline CASGoogle Scholar
• 84. Chekkat N, Lombardo CM, Seguin C et al. Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. Oncotarget 9(21), 15566–15578 (2018).
  MedlineGoogle Scholar
• 85. Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies 6(4), 16 (2017).
  Google Scholar
• 86. Liu H, Su D, Zhang J et al. Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci. Rep. 7(1), 8953 (2017).
  MedlineGoogle Scholar
• 87. Tao Z, Liu Y, Yang H et al. Customizing a tri-domain TRAIL variant to achieve active tumor homing and endogenous albumin-controlled release of the molecular machine in vivo. Biomacromolecules 21(10), 4017–4029 (2020).
  Medline CASGoogle Scholar
• 88. Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7(8), 954–960 (2001).
  Medline CASGoogle Scholar
• 89. Oliver PG, Lobuglio AF, Zhou T et al. Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast cancer Res. 133(2), 417–426 (2012).
  CASGoogle Scholar
• 90. Straughn JM Jr, Oliver PG, Zhou T et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 101(1), 46–54 (2006).
  Medline CASGoogle Scholar
• 91. Derosier LC, Huang ZQ, Sellers JC et al. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J. Gastrointest. Surg. 10(9), 1291–1300 (2006).
  MedlineGoogle Scholar
• 92. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 251(1), 146–157 (2007).
  Medline CASGoogle Scholar
• 93. Yada A, Yazawa M, Ishida S et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann. Oncol. 19(6), 1060–1067 (2008).
  Medline CASGoogle Scholar
• 94. Kaplan-Lefko PJ, Graves JD, Zoog SJ et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 9(8), 618–631 (2010).
  Medline CASGoogle Scholar
• 95. Rosevear HM, Lightfoot AJ, Griffith TS. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Curr. Opin. Investig. Drugs 11(6), 688–698 (2010).
  Medline CASGoogle Scholar
• 96. Oliver PG, Lobuglio AF, Zinn KR et al. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin. Cancer Res. 14(7), 2180–2189 (2008).
  Medline CASGoogle Scholar
• 97. Legler K, Hauser C, Egberts JH et al. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis. 9(5), 445 (2018).
  MedlineGoogle Scholar
• 98. Von Pawel J, Harvey JH, Spigel DR et al. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 15(3), 188–196 e182 (2014).
  Medline CASGoogle Scholar
• 99. Dhein J, Daniel PT, Trauth BC et al. Induction of apoptosis by monoclonal antibody anti-apo-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149(10), 3166–3173 (1992).
  Medline CASGoogle Scholar
• 100. Adams C, Totpal K, Lawrence D et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody apomab and the proapoptotic receptor DR5. Cell Death Differ. 15(4), 751–761 (2008).
  Medline CASGoogle Scholar
• 101. Holland PM. Targeting apo2L/TRAIL receptors by soluble apo2L/TRAIL. Cancer Lett. 332(2), 156–162 (2013).
  Medline CASGoogle Scholar
• 102. Huet HA, Growney JD, Johnson JA et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. mAbs 6(6), 1560–1570 (2014).
  MedlineGoogle Scholar
• 103. Papadopoulos KP, Isaacs R, Bilic S et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother. Pharmacol. 75(5), 887–895 (2015).
  Medline CASGoogle Scholar
• 104. Strater J, Hinz U, Walczak H et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 8(12), 3734–3740 (2002).
  MedlineGoogle Scholar
• 105. Spierings DC, De Vries EG, Timens W et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin. Cancer Res. 9(9), 3397–3405 (2003).
  Medline CASGoogle Scholar
• 106. Kriegl L, Jung A, Engel J et al. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin. Cancer Res. 16(22), 5529–5538 (2010).
  Medline CASGoogle Scholar
• 107. Gundlach JP, Hauser C, Schlegel FM et al. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. BMC Cancer 18(1), 777 (2018).
  MedlineGoogle Scholar
• 108. Omran OM, Ata HS. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer. Am. J. Dermatopathol. 36(9), 710–717 (2014).
  MedlineGoogle Scholar
• 109. Devetzi M, Kosmidou V, Vlassi M et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci. Rep. 6, 36532 (2016).
  Medline CASGoogle Scholar
• 110. Singh D, Prasad CB, Biswas D et al. TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer. Pathology 52(3), 348–358 (2020).
  Medline CASGoogle Scholar
• 111. McCarthy MM, Sznol M, Divito KA et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin. Cancer Res. 11(14), 5188–5194 (2005).
  Medline CASGoogle Scholar
• 112. Kuijlen JM, Mooij JJ, Platteel I et al. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J. Neurooncol. 78(2), 161–171 (2006).
  Medline CASGoogle Scholar
• 113. Macher-Goeppinger S, Aulmann S, Tagscherer KE et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 15(2), 650–659 (2009).
  Medline CASGoogle Scholar
• 114. Gallmeier E, Bader DC, Kriegl L et al. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS ONE 8(2), e56760 (2013).
  Medline CASGoogle Scholar
• 115. Haselmann V, Kurz A, Bertsch U et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 146(1), 278–290 (2014).
  Medline CASGoogle Scholar
• 116. Granci V, Bibeau F, Kramar A et al. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur. J. Cancer 44(15), 2312–2318 (2008).
  Medline CASGoogle Scholar
• 117. Chamuleau ME, Ossenkoppele GJ, van Rhenen A et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res. 35(6), 741–749 (2011).
  Medline CASGoogle Scholar
• 118. Gottwald L, Pasz-Walczak G, Piekarski J et al. Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. J. Obstet. Gynaecol. 34(4), 346–349 (2014).
  Medline CASGoogle Scholar
• 119. Labovsky V, Martinez LM, Davies KM et al. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer 17(1), 280 (2017).
  MedlineGoogle Scholar
• 120. Narayan G, Xie D, Ishdorj G et al. Epigenetic inactivation of TRAIL decoy receptors at 8p12–21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer 55(2), 177–189 (2016).
  Medline CASGoogle Scholar
• 121. Ganten TM, Sykora J, Koschny R et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J. Mol. Med. 87(10), 995–1007 (2009).
  Medline CASGoogle Scholar
• 122. Bosch LJW, Trooskens G, Snaebjornsson P et al. Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget 8(38), 63140–63154 (2017).
  MedlineGoogle Scholar
• 123. Tsikalakis S, Chatziandreou I, Michalopoulos NV et al. Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. Pathol. Res. Pract. 214(6), 826–834 (2018).
  Medline CASGoogle Scholar
• 124. Wu X, Wang S, Li M et al. Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy. Nanoscale 9(37), 13879–13904 (2017).
  Medline CASGoogle Scholar
• 125. Kagawa S, He C, Gu J et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61(8), 3330–3338 (2001).
  Medline CASGoogle Scholar
• 126. De Miguel D, Basanez G, Sanchez D et al. Liposomes decorated with apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol. Pharm. 10(3), 893–904 (2013).
  MedlineGoogle Scholar
• 127. Hill AB, Chen M, Chen CK et al. Overcoming gene-delivery hurdles: physiological considerations for nonviral vectors. Trends Biotechnol. 34(2), 91–105 (2016).
  Medline CASGoogle Scholar
• 128. Griffith TS, Anderson RD, Davidson BL et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis. J. Immunol. 165(5), 2886–2894 (2000).
  Medline CASGoogle Scholar
• 129. Yin H, Kanasty RL, Eltoukhy AA et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15(8), 541–555 (2014).
  Medline CASGoogle Scholar
• 130. Kong H, Zhao R, Zhang Q et al. Biosilicified oncolytic adenovirus for cancer viral gene therapy. Biomater. Sci. 8, 5317–5328 (2020).
  Medline CASGoogle Scholar
• 131. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat. Rev. Drug Dis. 4(7), 581–593 (2005).
  Medline CASGoogle Scholar
• 132. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem. Rev. 109(2), 259–302 (2009).
  Medline CASGoogle Scholar
• 133. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92(16), 7297–7301 (1995).
  Medline CASGoogle Scholar
• 134. Wang S, Shao M, Zhong Z et al. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv. 24(1), 1791–1800 (2017).
  Medline CASGoogle Scholar
• 135. Li J, Gu B, Meng Q et al. The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 22(43), 435101 (2011).
  MedlineGoogle Scholar
• 136. Tzeng SY, Wilson DR, Hansen SK, Quinones-Hinojosa A, Green JJ. Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng. Transl. Med. 1(2), 149–159 (2016).
  Medline CASGoogle Scholar
• 137. Chen L, Mignani S, Caminade AM, Majoral JP. Metal-based phosphorus dendrimers as novel nanotherapeutic strategies to tackle cancers: A concise overview. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11(6), e1577 (2019).
  MedlineGoogle Scholar
• 138. Dianat-Moghadam H, Heidarifard M, Mahari A et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol. Res. 155, 104716 (2020).
  Medline CASGoogle Scholar
• 139. Wang K, Kievit FM, Jeon M et al. Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. Adv. Healthc. Mater. 4(17), 2719–2726 (2015).
  Medline CASGoogle Scholar
• 140. Chen Z, Zhang L, He Y, Li Y. Sandwich-type Au-PEI/DNA/PEI-Dexa nanocomplex for nucleus-targeted gene delivery in vitro and in vivo. ACS Appl. Mater. Inter. 6(16), 14196–14206 (2014).
  Medline CASGoogle Scholar
• 141. Belkahla H, Herlem G, Picaud F et al. TRAIL-NP hybrids for cancer therapy: a review. Nanoscale 9(18), 5755–5768 (2017).
  Medline CASGoogle Scholar
• 142. Martin ME, Rice KG. Peptide-guided gene delivery. The AAPS J. 9(1), E18–29 (2007).
  Medline CASGoogle Scholar
• 143. Dubuisson A, Favreau C, Fourmaux E et al. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization. Cell Death Dis. 10(2), 101 (2019).
  MedlineGoogle Scholar
• 144. Li L, Song L, Yang X et al. Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma. Biomaterials 111, 124–137 (2016).
  Medline CASGoogle Scholar
• 145. Li L, Li X, Wu Y et al. Multifunctional nucleus-targeting nanoparticles with ultra-high gene transfection efficiency for in vivo gene therapy. Theranostics 7(6), 1633–1649 (2017).
  Medline CASGoogle Scholar
• 146. Belkahla H, Mazario E, Sangnier AP et al. TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia. Theranostics 9(20), 5924–5936 (2019).
  Medline CASGoogle Scholar
• 147. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol. Ther. 13(12), 1143–1151 (2012).
  Medline CASGoogle Scholar
• 148. Altucci L, Rossin A, Raffelsberger W et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7(6), 680–686 (2001).
  Medline CASGoogle Scholar
• 149. Nebbioso A, Clarke N, Voltz E et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77–84 (2005).
  Medline CASGoogle Scholar
• 150. Elmallah MIY, Micheau O. Epigenetic regulation of TRAIL signaling: implication for cancer therapy. Cancers 11(6)2019).
  MedlineGoogle Scholar
• 151. Xu J, Zhou JY, Wu GS. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 66(20), 10092–10099 (2006).
  Medline CASGoogle Scholar
• 152. Xu J, Zhou JY, Tainsky MA, Wu GS. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 67(3), 1203–1211 (2007).
  Medline CASGoogle Scholar
• 153. Xu J, Zhou JY, Wei WZ et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 68(16), 6718–6726 (2008).
  Medline CASGoogle Scholar
• 154. Allen JE, Krigsfeld G, Mayes PA et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl. Med. 5(171), 171ra117 (2013).
  Google Scholar
• 155. Allen JE, Kline CL, Prabhu VV et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45), 74380–74392 (2016).
  MedlineGoogle Scholar
• 156. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res. 75(7), 1423–1432 (2015).
  Medline CASGoogle Scholar
• 157. Ishizawa J, Kojima K, Chachad D et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci. Signal. 9(415), ra17 (2016).
  MedlineGoogle Scholar
• 158. Yuan X, Kho D, Xu J et al. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget 8(13), 21626–21638 (2017).
  MedlineGoogle Scholar
• 159. Stein MN, Bertino JR, Kaufman HL et al. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin. Cancer Res. 23(15), 4163–4169 (2017).
  Medline CASGoogle Scholar
• 160. Nagane M, Pan G, Weddle JJ et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60(4), 847–853 (2000).
  Medline CASGoogle Scholar
• 161. Wu XX, Kakehi Y, Mizutani Y et al. Enhancement of TRAIL/apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int. J. Cancer 104(4), 409–417 (2003).
  Medline CASGoogle Scholar
• 162. Gibson SB, Oyer R, Spalding AC et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell. Biol. 20(1), 205–212 (2000).
  Medline CASGoogle Scholar
• 163. Turner KA, Manouchehri JM, Kalafatis M. Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin. Melanoma Res. 28(4), 277–285 (2018).
  Medline CASGoogle Scholar
• 164. Zhu W, Zhan D, Wang L et al. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncol. Rep. 36(2), 845–852 (2016).
  Medline CASGoogle Scholar
• 165. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64(18), 6666–6672 (2004).
  Medline CASGoogle Scholar
• 166. Cheng H, Hong B, Zhou L et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell cycle 11(17), 3312–3323 (2012).
  Medline CASGoogle Scholar
• 167. Senbabaoglu F, Cingoz A, Kaya E et al. Identification of mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme. Cancer Biol. Ther. 17(5), 546–557 (2016).
  Medline CASGoogle Scholar
• 168. Baritaki S, Huerta-Yepez S, Sakai T et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer Ther. 6(4), 1387–1399 (2007).
  Medline CASGoogle Scholar
• 169. Meijer A, Kruyt FA, van der Zee AG et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br. J. Cancer 109(10), 2685–2695 (2013).
  Medline CASGoogle Scholar
• 170. Hori T, Kondo T, Kanamori M et al. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 287(1), 98–108 (2010).
  Medline CASGoogle Scholar
• 171. Lim SC, Parajuli KR, Han SI. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway. Tumour Biol. 37(5), 6205–6216 (2016).
  Medline CASGoogle Scholar
• 172. Fassl A, Tagscherer KE, Richter J et al. Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. Cell Death Dis. 6, e1921 (2015).
  Medline CASGoogle Scholar
• 173. Sung B, Prasad S, Ravindran J et al. Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic. Biol. Med. 53(10), 1977–1987 (2012).
  Medline CASGoogle Scholar
• 174. Yang J, Yang C, Zhang S et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol. Ther. 16(8), 1194–1204 (2015).
  Medline CASGoogle Scholar
• 175. Chen L, Meng Y, Sun Q et al. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. Cell Death Dis. 7(8), e2334 (2016).
  Medline CASGoogle Scholar
• 176. Yang J, Qian S, Cai X et al. Chikusetsusaponin IVa butyl ester (CS-IVa-Be), a novel IL6R antagonist, inhibits IL6/STAT3 signaling pathway and induces cancer cell apoptosis. Mol. Cancer Ther. 15(6), 1190–1200 (2016).
  Medline CASGoogle Scholar
• 177. Kim JH, Park B, Gupta SC et al. Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid. Redox Signal. 16(5), 413–427 (2012).
  Medline CASGoogle Scholar
• 178. Trivedi R, Maurya R, Mishra DP. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death Dis. 5, e1465 (2014).
  Medline CASGoogle Scholar
• 179. Chen W, Wang X, Zhuang J et al. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28(10), 2114–2121 (2007).
  Medline CASGoogle Scholar
• 180. Carter BZ, Mak DH, Schober WD et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108(2), 630–637 (2006).
  Medline CASGoogle Scholar
• 181. Wu B, Xiong J, Zhou Y et al. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Arch. Biochem. Biophys. 692, 108539 (2020).
  Medline CASGoogle Scholar
• 182. Ding J, Polier G, Kohler R et al. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J. Biol. Chem. 287(1), 641–649 (2012).
  Medline CASGoogle Scholar
• 183. Zhong HH, Wang HY, Li J, Huang YZ. TRAIL-based gene delivery and therapeutic strategies. Acta pharmacol. Sin. 40(11), 1373–1385 (2019).
  Medline CASGoogle Scholar